Finny Kuruvilla, MD, PhD joined Clarus Ventures from the Broad Institute of Harvard and MIT where he led a collaborative effort with Affymetrix (NASDAQ: AFFX) in medical and population genetics.  This work resulted in the development of  novel analytical tools and software that allow the massively parallel interrogation of clinical DNA samples, which has been used to study billions of genotypes in academic and industrial settings globally.  Prior to joining the Broad, Dr. Kuruvilla’s research focused on the elucidation of the mechanism of action of rapamycin.

Dr. Kuruvilla has cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders at the Brigham & Women’s Hospital, Children’s Hospital Boston, the Dana-Farber Cancer Institute, the Beth Israel Deaconess Medical Center, and the Massachusetts General Hospital.  He completed his residency at the Brigham & Women’s Hospital and his fellowship in transfusion medicine at Harvard Medical School. He received his M.D. from Harvard Medical School, his Ph.D. in chemistry and chemical biology from Harvard University, his master’s degree in electrical engineering and computer science from MIT, and his bachelor’s degree in chemistry from Caltech.

Dr. Kuruvilla is a Board observer for Lycera, Nanostring, Virdante, and is a member of the Scientific Advisory Board for Nanostring.

Michele Park, PhD, serves as a Principal of Clarus Ventures. Dr. Park joined Clarus with five years of sell-side equity research experience covering the biotechnology sector. From 2002-2005, Dr. Park was a research analyst at Credit Suisse First Boston, where she covered biotechnology stocks as a member of the firm’s US biotechnology team. Before joining CSFB, Dr. Park was a biotechnology research analyst at US Bancorp Piper Jaffray.

Dr. Park received a PhD in Molecular Biology from Cornell University’s Graduate School of Biomedical Sciences, completing her PhD dissertation at Memorial Sloan-Kettering Cancer Center, and a BA in Molecular Biology from Princeton University.

Dr. Park is a member of the Board of Directors for Sientra and Board observer for Achillion, and SFJ Pharmaceuticals, LP.